ArticlePaediatric drugs2018

Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability.

M A Cozijnsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.